Эффективность адъювантной терапии анастрозолом и тамоксифеном у пациенток с ранними стадиями рака молочной железы

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108. 
2. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36. 
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717. 
4. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296–300. 
5. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937–47. 
6. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profies and cardiovascular risk in postmenopausal women? Am Heart J 2007; 153: 182–88. 
7. Wysowski DK, Honig S, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346: 1832–33. 
8. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2. 
9. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486–92. 
10. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559–70. 
11. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29. 
12. Goldhirsch A, Wood W, Gelber R et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44. 
13. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: fist results of the ATAC randomised trial. Lancet 2002; 359: 2131–39. 
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10. 
15. The ATAC Trialists' Group. Comprehensive side-effect profie of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633–43. 
16. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846–52. 
17. Dowsett M, Allred DC, on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006; 100 (suppl. 1): S21 (abstr 48). 
18. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–220. 
19. Jones MC, Wand MP. Kernel smoothing. Boca Raton, FL: CRC Press, 1994. 
20. Food and Drug Administration (COSTART). The coding symbols for thesaurus of adverse reaction terms, 5th edn, 1995. 
21. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specifi mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007; 25: 4952–60. 
22. Coleman RE, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc Am Soc Clin Oncol 2006; 24 (suppl. 18): abstr 511. 
23. Eastell R, Adams JE, Coleman R et al. Effect of anastrozole on bone mineral density: 5-year results from the ATAC trial (18233230). J Clin Oncol (in press). 
24.Eastell R, Van Poznack C, Hannon RA et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. J Bone Miner Res 2007; 22 (suppl. 1): S113. 
25. Singh S, Cuzick J, Edward R et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). Breast Cancer Res Treat 2007; 106 (suppl. 1): S9, abstr 28. 
26. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.